Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE “Deidentified” ≠ “deidentifiable”

PharmaMar, Globant collaborate to accelerate oncology research with AI

Globant, a company focused on AI, and PharmaMar, developer of marine-derived anti-cancer drugs, announced a new collaboration designed to speed up cancer drug discovery through artificial intelligence.

February 20, 2026

Vol.52 No.07

Clinical Roundup

AI tool may help personalize ovarian cancer treatment from day one

Researchers from the University of Minnesota Medical School, in collaboration with Emory University and the Georgia Institute of Technology, have developed a new artificial intelligence biomarker tool that may help predict how ovarian cancer patients will respond to treatment at the time of diagnosis.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Most patients support use of AI to help read mammograms with doctor oversight, UTSW survey finds

UT Southwestern Medical Center researchers found that most patients support the use of AI to help interpret mammograms as long as radiologists provide oversight in the imaging analysis, although perceptions varied among patient populations.

January 30, 2026

Vol.52 No.04

Drugs & Targets

ACR names University Hospital of Bern first international ARCH AI Site

The American College of Radiology announced that Inselspital, the University Hospital of Bern, Switzerland, is the first international institution to participate in the ACR Recognized Center for Healthcare-AI program for artificial intelligence governance in radiology.

January 30, 2026

Vol.52 No.04

Cancer Policy

FDA releases 10 guiding principles for AI use in drug development

FDA, in collaboration with the European Medicines Agency, has published 10 principles to help guide pharmaceutical companies using artificial intelligence to develop drug, biological, and medical devices.

January 16, 2026

Vol.52 No.02

By Sara Willa Ernst